| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2022 | HIMS Hims & Hers Health, Inc. | Dudum Andrew48 | Chief Executive Officer | Buy | 1,500 | $5.17 | $7,755.00 | New | +1.9% | +50.6% | |
| Jan 19, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 25,639 | $65.28 | $1,673,642.09 | -27.6% | +15.1% | -42.3% | |
| Jan 18, 2022 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,242 | $26.93 | $33,447.06 | -2.0% | +131.6% | +110.9% | |
| Jan 18, 2022 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Senior Vice President, Finance | Sell | 2,500 | $64.97 | $162,430.00 | -14.2% | +14.3% | -41.2% | |
| Jan 18, 2022 | PCRX Pacira Biosciences, Inc. | Molloy Anthony74 | Chief Lgl &Compliance Officer | Sell | 224 | $63.55 | $14,235.20 | -1.3% | +14.3% | -41.2% | |
| Jan 18, 2022 | BHC Bausch Health Companies Inc. | Spurr Robert82 | U.s. President-pharma Business | Sell | 3,251 | $26.63 | $86,574.13 | -4.9% | -21.0% | -70.3% | |
| Jan 13, 2022 | LFCR Lifecore Biomedical, Inc. \de\ | Wynnefield Partners Small Cap Value LP I65 | 10% Owner | Buy | 387,400 | $10.41 | $4,032,245.00 | +3.8% | -3.6% | -34.6% | |
| Jan 12, 2022 | LFCR Lifecore Biomedical, Inc. \de\ | Schechter Joshua52 | Director | Buy | 10,000 | $10.39 | $103,940.00 | +185.3% | +0.3% | -31.2% | |
| Jan 11, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Viking Global Investors LP66 | 10% Owner | Buy | 2,300,000 | $19.00 | $43,700,000.00 | New | -37.4% | +81.3% | |
| Jan 11, 2022 | BCRX Biocryst Pharmaceuticals Inc | Stonehouse Jon P80 | President &CEO | Sell | 184,000 | $15.04 | $2,767,360.00 | -16.9% | -33.8% | -39.0% | |
| Jan 11, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Morningside Venture Investments Ltd93 | 10% Owner | Buy | 263,158 | $19.00 | $5,000,002.00 | +2.5% | -37.4% | +81.3% | |
| Jan 10, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 20,928 | $25.36 | $530,683.78 | -11.4% | +59.7% | +8.8% | |
| Jan 10, 2022 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 2,632 | $74.50 | $196,087.68 | -11.0% | +28.8% | +43.6% | |
| Jan 10, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 47,776 | $24.75 | $1,182,622.40 | -12.6% | +59.7% | +8.8% | |
| Jan 6, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Cheng Isaac | Director | Buy | 6,578 | $19.00 | $124,982.00 | New | -23.9% | +104.7% | |
| Jan 6, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Olinger Margaret | Chief Commercial Officer | Buy | 6,842 | $19.00 | $129,998.00 | +3.3% | -23.9% | +104.7% | |
| Jan 6, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Fonteyne Paul R. | Director | Buy | 3,947 | $19.00 | $74,993.00 | New | -23.9% | +104.7% | |
| Jan 6, 2022 | INM Inmed Pharmaceuticals Inc. | Johnson Shane Aaron | SVP, Gm Of Baymedica LLC | Buy | 8,500 | $1.26 | $10,710.00 | +2.9% | -31.3% | -94.9% | |
| Jan 6, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $192.46 | $1,154,786.96 | -5.7% | -5.4% | +40.9% | |
| Jan 6, 2022 | AMLX Amylyx Pharmaceuticals, Inc. | Milne George M Jr59 | Director | Buy | 26,315 | $19.00 | $499,985.00 | +13.5% | -23.9% | +104.7% | |
| Jan 5, 2022 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 28,266 | $85.50 | $2,416,751.48 | -21.2% | +16.6% | +47.7% | |
| Jan 3, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $23.22 | $11,608.65 | -0.6% | +64.2% | +22.2% | |
| Jan 3, 2022 | LNTH Lantheus Holdings, Inc. | Heino Mary Anne50 | President &CEO | Sell | 14,100 | $28.61 | $403,412.28 | -2.1% | +94.5% | +73.8% | |
| Jan 3, 2022 | AKBA Akebia Therapeutics, Inc. | Cotreau Violetta | SVP, Chief Accounting Officer | Sell | 5,833 | $2.29 | $13,335.40 | -15.0% | -73.1% | -74.6% | |
| Dec 30, 2021 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 3,614 | $279.55 | $1,010,275.63 | - | +5.0% | +33.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.